INOVIO to Present Three Posters at IDWeek 2021

Rhea-AI Summary

INOVIO (NASDAQ: INO), a biotechnology company, will showcase three posters at IDWeek 2021, held virtually from September 29 to October 3. Dr. Laurent M. Humeau stated that these presentations highlight their DNA vaccine candidates targeting COVID-19. The showcased abstracts include safety and immunogenicity data for INO-4800, which induced neutralizing antibodies and T-cell activity against SARS-CoV-2 variants. INOVIO focuses on developing DNA medicines for infectious diseases, with a strong track record of over 3,900 patients treated in clinical trials.

PLYMOUTH MEETING, Pa., Sept. 29, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, will present three posters at IDWeek 2021, taking place virtually from September 29^th - October 3^rd.

Dr. Laurent M. Humeau, INOVIO's Chief Scientific Officer, said, "We are excited to participate in our first IDWeek with the presentation of three posters that confirm our approach of developing DNA vaccines to combat the ongoing COVID-19 pandemic. Our vaccine candidates' study results have demonstrated INOVIO's platform-wide safety and tolerability profile, as well as the ability to generate CD8 and CD4 T cells and neutralizing antibodies against SARS-CoV-2 and variants of concern. We look forward to sharing our work with infectious disease experts around the world and hope they find the results generated by DNA COVID-19 vaccines to be very impactful."

The following abstracts and presentations are currently available for meeting attendees viewing:

• Abstract #571: Safety and Immunogenicity of INO-4800, a COVID-19 DNA Vaccine as a Primary Series and Booster
• Abstract #578: INO-4800 DNA Vaccine Induces Neutralizing Antibodies and T cell Activity Against Global SARS-CoV-2 Variants
• Abstract #579: Design and immunogenicity of a Pan-SARS-CoV-2 synthetic DNA vaccine

About INOVIO's DNA Medicines Platform

INOVIO has 15 DNA medicine clinical programs currently in development focused on HPV-associated diseases, cancer, and infectious diseases, including coronaviruses associated with COVID-19 and MERS. DNA medicines are composed of optimized DNA plasmids, which are small circles of double-stranded DNA that are synthesized or reorganized by a computer sequencing technology and designed to produce a specific immune response in the body.

INOVIO's DNA medicines deliver optimized plasmids directly into cells intramuscularly or intradermally using INOVIO's proprietary hand-held smart device called CELLECTRA^®. The CELLECTRA^® device uses a brief electrical pulse to reversibly open small pores in the cell to allow the plasmids to enter, which is designed to overcome a key limitation of other DNA and other nucleic acid approaches, such as mRNA. Once inside the cell, the DNA plasmids enable the cell to produce the targeted antigen. The antigen is processed naturally in the cell and triggers the desired T cell and antibody-mediated immune responses. Administration with the CELLECTRA^® device is designed to ensure that the DNA medicine is efficiently delivered directly into the body's cells, where it can go to work to drive an immune response. INOVIO's DNA medicines do not interfere with or change in any way an individual's own DNA. The advantages of INOVIO's DNA medicine platform are how fast DNA medicines can be designed and manufactured; the stability of the products, which do not require freezing in storage and transport; and the robust immune response, safety profile, and tolerability that have been observed in clinical trials.

With more than 3,900 patients receiving INOVIO investigational DNA medicines in more than 12,000 applications across a range of clinical trials, INOVIO has a strong track record of rapidly generating DNA medicine candidates with potential to meet urgent global health needs.

About INOVIO

INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO is the first company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. Specifically, INOVIO's lead candidate VGX-3100 met primary and secondary endpoints for all evaluable subjects in REVEAL 1, the first of two, Phase 3 trials for precancerous cervical dysplasia, demonstrating ability to destroy and clear both high-grade cervical lesions and the underlying high-risk HPV-16/18. INOVIO is also evaluating INO-4800, a DNA vaccine candidate against COVID-19, in a global Phase 3 clinical trial, as well as Phase 2 trials in China and South Korea.

Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency/Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense/Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. For more information, visit www.inovio.com.

CONTACTS:

Media: Jeff Richardson, 267-440-4211, jrichardson@inovio.com
Investors: Ben Matone, 484-362-0076, ben.matone@inovio.com

This press release contains certain forward-looking statements relating to our business, including our plans to develop DNA medicines, our plans and expectations regarding manufacturing, our plans regarding development of an in-vitro diagnostic, our expectations regarding our research and development programs, including the planned initiation and conduct of preclinical studies and clinical trials and the availability and timing of data from those studies and trials, and our ability to successfully manufacture and produce large quantities of our product candidates if they receive regulatory approval. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, the structuring, initiation and outcomes of clinical trials, product development programs and commercialization activities and outcomes, our ability to secure sufficient manufacturing capacity to mass produce our product candidates, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2020, our Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law.

 

View original content:https://www.prnewswire.com/news-releases/inovio-to-present-three-posters-at-idweek-2021-301387566.html

SOURCE INOVIO Pharmaceuticals, Inc.

FAQ

What is INOVIO presenting at IDWeek 2021?

INOVIO will present three posters at IDWeek 2021, showcasing their DNA vaccine candidates for COVID-19.

When is IDWeek 2021?

IDWeek 2021 takes place virtually from September 29 to October 3, 2021.

What does INO-4800 target?

INO-4800 is a DNA vaccine candidate developed by INOVIO targeting COVID-19.

What were the findings related to INO-4800?

Studies have shown INO-4800's safety, immunogenicity, and its ability to generate neutralizing antibodies against SARS-CoV-2 variants.

What is the focus of INOVIO's research efforts?

INOVIO focuses on DNA medicines for infectious diseases, cancer, and diseases associated with HPV.